Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accounts Payables (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Accounts Payables for 7 consecutive years, with $6.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables rose 134.71% to $6.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.9 million, a 134.71% increase, with the full-year FY2024 number at $4.4 million, up 24.78% from a year prior.
  • Accounts Payables was $6.9 million for Q3 2025 at 4D Molecular Therapeutics, down from $8.7 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $8.7 million in Q2 2025 to a low of $1.3 million in Q1 2021.
  • A 5-year average of $3.8 million and a median of $3.5 million in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: crashed 60.14% in 2022, then surged 218.45% in 2023.
  • 4D Molecular Therapeutics' Accounts Payables stood at $4.8 million in 2021, then plummeted by 30.27% to $3.3 million in 2022, then rose by 5.81% to $3.5 million in 2023, then increased by 24.78% to $4.4 million in 2024, then surged by 56.48% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Accounts Payables are $6.9 million (Q3 2025), $8.7 million (Q2 2025), and $4.2 million (Q1 2025).